01 (Image 01)
Nifedipine Tablet, Extended Release
Product Images NDC 71335-2132
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 71335-2132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
02 (Image 02)
This is a list of adverse effects caused by Nifedipine extended-release tablets compared to placebo based on a study with 707 participants. The adverse effects include headache, fatigue, dizziness, constipation, and nausea, with percentages ranging from 3.3% to 33%. The placebo group had lower percentages of adverse effects.*
03 (Image 03)
This is a table containing the percentage of a number of adverse effects experienced by two groups of patients (one group taking Nifedipine capsules and the other group taking a placebo). The adverse effects listed include dizziness, lightheadedness, giddiness, flushing, heat sensation, headache, weakness, nausea, heartburn, muscle cramps, tremor, peripheral edema, nervousness, mood changes, palpitations, dyspnea, cough wheezing, nasal congestion, and sore throat.*
Label (Lbl713352132)
This seems to be a medication label with information about a 90mg tablet of Nifedipine ER, manufactured by Novast Laboratories. The label includes instructions to store the medication at room temperature and keep it out of reach of children, as well as a lot number and expiration date.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
